<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741845</url>
  </required_header>
  <id_info>
    <org_study_id>Embil-2008Peru</org_study_id>
    <nct_id>NCT00741845</nct_id>
  </id_info>
  <brief_title>Prevention of Persistence of Bacterial Vaginosis</brief_title>
  <official_title>Prevention of Persistence of Bacterial Vaginosis: The Effects of High Dose Intravaginal Metronidazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Embil Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Embil Pharmaceutical Co. Ltd</source>
  <brief_summary>
    <textblock>
      This purpose of this study will be to conduct a double-blind, randomized, controlled clinical
      trial to determine the association between intravaginal high dose metronidazole (750mg),
      intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole +
      200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of
      persistent bacterial vaginosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for site documentation and monitoring issues - not safety, study drug, or adverse
    event issues.
  </why_stopped>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The specific aim of this study is to compare the rate of persistence of BV in non-pregnant women randomized to one of three different schemes of intravaginal metronidazole given nightly for 5 nights</measure>
    <time_frame>28 days after therapy initiation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravaginal metronidazole 750mg + 200mg miconazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravaginal metronidazole 750mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravaginal metronidazole 37.5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravaginal metronidazole</intervention_name>
    <description>high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women 18-40 yrs old

          -  abnormal vaginal discharge or malodor

          -  positive QuickVue test

          -  positive KOH whiff test

          -  Positive finding of clue cells greater than or equal to 20% on wet mount

          -  Able to give informed consent

          -  willing to abstain from alcohol during the 5 day therapy and 1 day following

        Exclusion Criteria:

          -  immunocompromised women

          -  symptomatic VVC

          -  pregnancy or positive pregnancy test

          -  menstruating or breastfeeding women

          -  other oral or vaginal antifungal or antimicrobial drugs w/in past 2 wks

          -  women with MPC, PID
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cayetano Heredia Hospital</name>
      <address>
        <city>Lima</city>
        <state>Urb Ingenieria</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 27, 2013</submitted>
    <returned>April 8, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

